Important Background Information on RSV for Pharmacists

Traci M. Poole, PharmD, BCACP, BCGP, discusses the pathophysiology of respiratory syncytial virus (RSV) and its key complications, identifies high-risk populations for severe RSV infection, and explores best practices for recognizing these patients and ensuring they receive timely vaccination to prevent serious outcomes.

Now Viewing

EP: 1.Important Background Information on RSV for Pharmacists

EP: 2.Pathophysiology and Complications Associated With Respiratory Syncytial Virus (RSV)

EP: 3.Exploring High-Risk Populations for RSV Complications

EP: 4.Implied Vaccine Burden and Associated Misinformation

EP: 5.Targeting Patients at Risk for Severe RSV Disease

EP: 6.Key Differences Between FDA-Approved RSV Vaccines

EP: 7.Ideal Patient Populations for RSV Vaccination

EP: 8.Pertinent Information for Shared Decision-Making

EP: 9.Additional Clinical Considerations for RSV Vaccination

EP: 10.Common Causes of RSV Vaccine Hesitancy

EP: 11.Building Trust With Vaccine-Hesitant Patients

EP: 12.Optimizing Multidisciplinary Care in RSV Vaccination Efforts

EP: 13.Best Practices in the Coadministration of Respiratory Vaccines

EP: 14.Future Management Considerations of RSV

Video content above is prompted by the following:

1. What is the pathophysiology of RSV and the key complications that can arise?
2. Who are the high-risk populations for getting severe RSV infection?
3. What are the best practices for identifying these patients and ensuring that they are vaccinated against RSV?

Related Videos